CORE--CENTRAL VIRUS CULTURE

核心--中心病毒培养

基本信息

项目摘要

The UAB CFAR has operated a Central Virus Core (CVC) shared resource since 1988. The specific aims of this core are: (1) To provide specially- designed and centrally-located BSL 2-3 laboratory space to all UAB investigators so that infectious HIV research can by physically restricted to specified areas; (2) To provide and maintain the high cost equipment needed for basic HIV research within the core facility in order to facilitate and broaden the research capabilities of all investigators and to avoid redundancy in equipment purchases; (3) To provide ongoing training, supervision, and monitoring of investigators and their research staff regarding BSL 2-3 practices required for HIV research with the CVC; (4) To foster the development of HIV/AIDS research by new and established investigators by providing a CVC staff with broad experience in basic and clinical HIV research which is dedicated to these goals. The CVC consists of two centrally-located biosafety level 2-3 (BSL 2-3) laboratories and their associated professional and technical staff. These laboratories are centrally located on the UAB campus in the vicinity of the greatest concentrations of HIV researchers. Together, they constitute 2500 square feet of BSL 2-3 laboratory space including nine self-contained 100 square foot tissue culture suites. Both the individual culture suites and the outer common equipment areas are completely equipped for molecular, biological, and clinical HIV research. The core is operated under the specific usages and priority guidelines established by the Core's Advisory Committee and complies with NIH/CDC recommendations for safe operating procedures. Since funded in 1988, the research of 45 principal investigators with federally funded grants have been accommodated in these facilities. Currently, the CVC supports the research of 24 UAB faculty representing 11 different departments and divisions within the School of Medicine. The CVC has trained, supervised, and assisted 105 researchers including graduated students, postdoctoral fellows, technicians, and faculty. Currently, there are a total of 64 active CVC users. In addition to R01-type projects, the CVC has supporter the research of major NIH funded program projects and contracts awarded to UAB investigators since 1988, including NCDDG, NCVDG, PEBRA, ACTG, AVEU, NICHD and HIV Genetic Variation projects. Over 300 peer-reviewed scientific publications have results from work performed within the CVC since 1993. Funding is requested to support the basic infrastructure costs of the CVC that remain despite a substantial chargeback system.
自那时以来,UAB CFAR一直运行中央病毒核心(CVC)共享资源

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN Christopher KAPPES其他文献

JOHN Christopher KAPPES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN Christopher KAPPES', 18)}}的其他基金

The effects of masculinizing gender-affirming hormone therapy for transgender men on susceptibility to HIV-1 infection modelled ex vivo in cervical mucosal tissue
跨性别男性男性化性别肯定激素治疗对子宫颈粘膜组织离体 HIV-1 感染易感性的影响
  • 批准号:
    10748946
  • 财政年份:
    2023
  • 资助金额:
    $ 14.28万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    10553626
  • 财政年份:
    2020
  • 资助金额:
    $ 14.28万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    10428455
  • 财政年份:
    2020
  • 资助金额:
    $ 14.28万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    9892706
  • 财政年份:
    2020
  • 资助金额:
    $ 14.28万
  • 项目类别:
Analysis of human uterine mucosal cells as targets of HIV-1 infection
人类子宫粘膜细胞作为 HIV-1 感染靶点的分析
  • 批准号:
    8925576
  • 财政年份:
    2015
  • 资助金额:
    $ 14.28万
  • 项目类别:
Virology
病毒学
  • 批准号:
    7685030
  • 财政年份:
    2009
  • 资助金额:
    $ 14.28万
  • 项目类别:
Virology
病毒学
  • 批准号:
    7697009
  • 财政年份:
    2008
  • 资助金额:
    $ 14.28万
  • 项目类别:
Single cycle reporter assay for quantifying HIV-1 Nab
用于量化 HIV-1 Nab 的单循环报告基因检测
  • 批准号:
    6694007
  • 财政年份:
    2003
  • 资助金额:
    $ 14.28万
  • 项目类别:
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION
逆转录整合酶分析
  • 批准号:
    6511302
  • 财政年份:
    2000
  • 资助金额:
    $ 14.28万
  • 项目类别:
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION
逆转录整合酶分析
  • 批准号:
    6632295
  • 财政年份:
    2000
  • 资助金额:
    $ 14.28万
  • 项目类别:

相似海外基金

CORE--BIOHAZARD CONTROL
核心——生物危害控制
  • 批准号:
    6353462
  • 财政年份:
    2000
  • 资助金额:
    $ 14.28万
  • 项目类别:
CORE--BIOHAZARD CONTROL
核心——生物危害控制
  • 批准号:
    6201408
  • 财政年份:
    1999
  • 资助金额:
    $ 14.28万
  • 项目类别:
CORE--BIOHAZARD CONTROL
核心——生物危害控制
  • 批准号:
    6100201
  • 财政年份:
    1998
  • 资助金额:
    $ 14.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了